CA2826262C - Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire - Google Patents

Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire Download PDF

Info

Publication number
CA2826262C
CA2826262C CA2826262A CA2826262A CA2826262C CA 2826262 C CA2826262 C CA 2826262C CA 2826262 A CA2826262 A CA 2826262A CA 2826262 A CA2826262 A CA 2826262A CA 2826262 C CA2826262 C CA 2826262C
Authority
CA
Canada
Prior art keywords
pih
acne
reducing
treatment
inflammatory hyperpigmentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2826262A
Other languages
English (en)
Other versions
CA2826262A1 (fr
Inventor
Mei Feng Hong
Qi Jia
Lidia Alfaro Brownell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unigen Inc
Original Assignee
Unigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unigen Inc filed Critical Unigen Inc
Priority to CA3128718A priority Critical patent/CA3128718A1/fr
Priority to CA3128715A priority patent/CA3128715A1/fr
Priority to CA3128711A priority patent/CA3128711C/fr
Priority claimed from PCT/US2012/023686 external-priority patent/WO2012106551A1/fr
Publication of CA2826262A1 publication Critical patent/CA2826262A1/fr
Application granted granted Critical
Publication of CA2826262C publication Critical patent/CA2826262C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des procédés de traitement d'une pigmentation excessive, comprenant le traitement d'une hyperpigmentation post-inflammatoire (PIH). Les procédés décrits comprennent l'administration d'une composition comprenant du bakuchiol sensiblement exempt de furanocoumarines à un mammifère. L'invention porte également sur des compositions comprenant du bakuchiol et sur leurs procédés de préparation.
CA2826262A 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire Active CA2826262C (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA3128718A CA3128718A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128715A CA3128715A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128711A CA3128711C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161438890P 2011-02-02 2011-02-02
US61/438,890 2011-02-02
USPCT/US2011/026594 2011-03-01
PCT/US2011/026594 WO2012105990A1 (fr) 2011-02-02 2011-03-01 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
PCT/US2012/023686 WO2012106551A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CA3128715A Division CA3128715A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128711A Division CA3128711C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128718A Division CA3128718A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Publications (2)

Publication Number Publication Date
CA2826262A1 CA2826262A1 (fr) 2012-08-09
CA2826262C true CA2826262C (fr) 2021-10-26

Family

ID=46603028

Family Applications (4)

Application Number Title Priority Date Filing Date
CA2826262A Active CA2826262C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128718A Pending CA3128718A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128711A Active CA3128711C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128715A Pending CA3128715A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA3128718A Pending CA3128718A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128711A Active CA3128711C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128715A Pending CA3128715A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Country Status (8)

Country Link
KR (5) KR102525516B1 (fr)
CN (2) CN103458882B (fr)
AU (1) AU2012212153B9 (fr)
BR (1) BR112013019798A2 (fr)
CA (4) CA2826262C (fr)
MX (1) MX350719B (fr)
PH (1) PH12013501632A1 (fr)
WO (1) WO2012105990A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471035B2 (en) 2014-10-20 2019-11-12 Sunny BioDiscovery Compositions and methods for using esters of meroterpenes and of other resveratrol analogues
CN105675741A (zh) * 2015-12-30 2016-06-15 成都九芝堂金鼎药业有限公司 一种测定生发丸中有效成分含量的方法
KR20190116858A (ko) 2018-04-05 2019-10-15 주식회사 엑소코바이오 줄기세포 유래의 엑소좀 및/또는 세포외 소포체를 유효성분으로 포함하는 조성물의 염증후 과색소침착의 예방, 완화, 감소 내지는 제거 용도
KR102610938B1 (ko) 2018-08-31 2023-12-08 (주)아모레퍼시픽 유화입자를 형성하는 나노캡슐 및 이를 포함하는 유화 조성물
KR102887367B1 (ko) * 2020-02-27 2025-11-14 (주)아모레퍼시픽 보습 효과를 갖는 조성물
CN111544317B (zh) * 2020-04-29 2022-01-14 珀莱雅化妆品股份有限公司 一种抗衰老组合物阳离子纳米脂质体及其制备方法与应用
CN114478196B (zh) * 2021-01-27 2023-11-10 江苏巴帝恩生物科技有限公司 一种从春榆根里提取补骨脂酚并纯化的方法及在化妆品中的应用
US20250018312A1 (en) * 2023-07-03 2025-01-16 Anju Majeed Furanocoumarins free bakuchiol compositions and their method of preparation thereof
CN117771298A (zh) * 2023-11-23 2024-03-29 常州大学 一种具有抗黑色素生成活性的组合物及其制备方法
KR102899265B1 (ko) * 2024-03-29 2025-12-10 한국세라믹기술원 항산화 및 항염 활성이 개선된 바쿠치올 나노입자의 제조 방법 및 상기 방법에 의해 제조된 바쿠치올 나노입자의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617473B2 (ja) 1987-06-30 1997-06-04 キヤノン株式会社 情報入力装置
CN101217968B (zh) * 2005-05-09 2014-11-26 尤尼根公司 补骨脂酚的组合物及其制备方法
WO2008140673A1 (fr) * 2007-05-14 2008-11-20 Sytheon Ltd. Compositions de traitement pour la peau et procédés

Also Published As

Publication number Publication date
CA2826262A1 (fr) 2012-08-09
AU2012212153A1 (en) 2013-08-29
CA3128718A1 (fr) 2012-08-09
KR102525516B1 (ko) 2023-04-24
KR20230058727A (ko) 2023-05-03
KR102642352B1 (ko) 2024-02-28
CA3128715A1 (fr) 2012-08-09
HK1215792A1 (zh) 2016-09-15
CN105147533B (zh) 2018-07-31
WO2012105990A1 (fr) 2012-08-09
KR102156731B1 (ko) 2020-09-16
KR101954118B1 (ko) 2019-03-05
CA3128711A1 (fr) 2012-08-09
KR102333655B1 (ko) 2021-12-01
AU2012212153B2 (en) 2017-04-06
MX2013008890A (es) 2013-10-17
BR112013019798A2 (pt) 2017-07-04
KR20210145864A (ko) 2021-12-02
KR20140008364A (ko) 2014-01-21
CA3128711C (fr) 2026-03-10
KR20200108120A (ko) 2020-09-16
KR20190025740A (ko) 2019-03-11
CN103458882B (zh) 2015-08-05
CN105147533A (zh) 2015-12-16
MX350719B (es) 2017-09-14
AU2012212153B9 (en) 2017-05-11
CN103458882A (zh) 2013-12-18
PH12013501632A1 (en) 2019-03-22

Similar Documents

Publication Publication Date Title
CA2826262C (fr) Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
PH12014501639A1 (en) Pharmaceutical compositions and methods
MX2014001318A (es) Composiciones para el cuidado de la piel que contienen combinaciones de ingredientes naturales.
PH12013501427B1 (en) Melanin modification compositions and methods of use
WO2012075419A3 (fr) Élimination de la graisse par un traitement hyperthermique non invasif
MX2012000817A (es) Tratamiento para desordenes del higado con inhibidores pi3k.
PL2758381T3 (pl) PREPARATY KOSMETYCZNE LUB DERMATOLOGICZNE ZAWIERAJĄCE AMIDOTIAZOLE ALKILOWE I ICH STOSOWANIE W CELU USUWANIA NIEPOŻĄDANYCH PRZEBARWIEŃ SKÓRY i ZAPOBIEGANIA ICH POWSTAWANIU
MX352165B (es) Compuestos con actividad anti-envejecimiento.
NZ600874A (en) Fluorinated derivatives of deferiprone
WO2010097788A3 (fr) Agents thérapeutiques de visfatine pour traiter l'acné et d'autres conditions
CA3010395A1 (fr) Procede de traitement de la peau avec des modulateurs de microarn
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
WO2011125039A3 (fr) Utilisation cosmétique du géranylgéranyl-2-propanol
EP2685993B8 (fr) Composition comprenant des sécrétions de tissus adipeux pour son utilisation tpoique dans le traitement et la prévention de l'acné
WO2014008477A3 (fr) Activation du canal ionique trpv4 par stimuli physiques et rôle critique de trpv4 dans l'inflammation et la démangeaison spécifique à un organe
GB201316955D0 (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
MX2014003449A (es) Heterociclocarbonilaminotiazoles, preparaciones cosmeticas o dermatologicas que contienen los mismos y su uso para el control y la profilaxis de pigmentacion indeseada de la piel.
WO2010015965A3 (fr) Procédés et compositions de traitement d'un dommage neuronal et de modulation de canaux potentiels de récepteurs transitoires
PH12017501200A1 (en) A skin lightening composition comprising niacinamide and ilomastat
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
SMT202100525T1 (it) Trattamento topico per la prevenzione e la mitigazione della citotossicita' cutanea dovuta a farmaci inibitori delle tirosin-chinasi
WO2013140153A3 (fr) Utilisations cosmétiques et pharmaceutiques de saccharides
PH12012000153A1 (en) Divalent cation/talc containing compositions and methods for treating and/or preventing enzymatic irritation
MY189383A (en) Soyasaponin-containing composition for skin whitening
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170201

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250124